ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
- Registry ID
- CA266-0004
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- BRISTOL-MYERS SQUIBB CANADA
- Start date
- 2026-06-08
- Last update
- 2025-12-18
Conditions
- GASTRIC CANCER
- ESOPHAGEAL CANCER
- GASTROESOPHAGEAL JUNCTION CANCER
- GASTROESOPHAGEAL ADENOCARCINOMA
Related clinical trials
- AACR ADAPTIVE BIOMARKER-DRIVEN ORGAN PRESERVATION TRIAL IN GASTROESOPHAGEAL ADENOCARCINOMAS
- A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY OF SONESITATUG VEDOTIN IN
COMBINATION WITH FLUOROPYRIMIDINE WITH OR WITHOUT RILVEGOSTOMIG IN FIRST-LINE
CLAUDIN18.2-POSITIVE, HER2-NEGATIVE, ADVANCED/METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
(CLARITY-GASTRIC 02)
- A MASTER PROTOCOL FOR AN OPEN-LABEL, MULTI-DRUG, MULTI-CENTER,
PHASE II PLATFORM STUDY TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF NOVEL
AGENTS OR COMBINATIONS AS PERIOPERATIVE TREATMENT IN PARTICIPANTS
WITH LOCALLY ADVANCED RESECTABLE GASTROESOPHAGEAL
ADENOCARCINOMA (GEMINI-PERIOP GC)
- A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB
DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS
CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE
TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
HER2POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINYGASTRIC05)
- A PHASE 2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND OPTIMAL DOSE OF ABBV-400 IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND BUDIGALIMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (ANDROMETA-GEA-977)
- A RANDOMIZED, PHASE III STUDY OF RILVEGOSTOMIG IN COMBINATION WITH FLUOROPYRIMIDINE AND TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB, CHEMOTHERAPY, AND PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF HER2-POSITIVE GASTRIC CANCER (ARTEMIDE-GASTRIC01)
View on source registry